Literature DB >> 29555644

Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea.

Françoise Bernaudin1, Cécile Arnaud1, Annie Kamdem1, Isabelle Hau2, Françoise Lelong3, Ralph Epaud2, Corinne Pondarré1,4, Serge Pissard4,5.   

Abstract

Sickle cell anemia (SCA), albeit monogenic, has heterogeneous phenotypic expression, mainly related to the level of hemoglobin F (HbF). No large cohort studies have ever compared biological parameters in patients with major β-globin haplotypes; ie, Senegal (SEN), Benin (BEN), and Bantu/Central African Republic (CAR). The aim of this study was to evaluate the biological impact of α genes, β haplotypes, and glucose-6-phosphate dehydrogenase (G6PD) activity at baseline and with hydroxyurea (HU). Homozygous HbS patients from the Créteil pediatric cohort with available α-gene and β-haplotype data were included (n = 580; 301 females and 279 males) in this retrospective study. Homozygous β-haplotype patients represented 74% of cases (37.4% CAR/CAR, 24.3% BEN/BEN, and 12.1% SEN/SEN). HU was given to 168 cohort SCA children. Hematological parameters were recorded when HbF was maximal, and changes (ΔHU-T0) were calculated. At baseline, CAR-haplotype and α-gene numbers were independently and negatively correlated with Hb and positively correlated with lactate dehydrogenase. HbF was negatively correlated with CAR-haplotype numbers and positively with BEN- and SEN-haplotype numbers. The BCL11A/rs1427407 "T" allele, which is favorable for HbF expression, was positively correlated with BEN- and negatively correlated with CAR-haplotype numbers. With HU treatment, Δ and HbF values were positively correlated with the BEN-haplotype number. BEN/BEN patients had higher HbF and Hb levels than CAR/CAR and SEN/SEN patients. In conclusion, we show that BEN/BEN patients have the best response on HU and suggest that this could be related to the higher prevalence of the favorable BCL11A/rs1427407/T/allele for HbF expression in these patients.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29555644      PMCID: PMC5873235          DOI: 10.1182/bloodadvances.2017014555

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  60 in total

1.  Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia.

Authors:  Mehdi Nouraie; Noel S Reading; Andrew Campbell; Caterina P Minniti; Sohail R Rana; Lori Luchtman-Jones; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Josef T Prchal; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2010-05-09       Impact factor: 6.998

2.  Rapid analysis of -alpha 3.7 thalassaemia and alpha alpha alpha anti 3.7 triplication by enzymatic amplification analysis.

Authors:  C Dodé; R Krishnamoorthy; J Lamb; J Rochette
Journal:  Br J Haematol       Date:  1993-01       Impact factor: 6.998

3.  Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa.

Authors:  J Pagnier; J G Mears; O Dunda-Belkhodja; K E Schaefer-Rego; C Beldjord; R L Nagel; D Labie
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

Review 4.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

5.  Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure.

Authors:  Michael R DeBaun; Sharada A Sarnaik; Mark J Rodeghier; Caterina P Minniti; Thomas H Howard; Rathi V Iyer; Baba Inusa; Paul T Telfer; Melanie Kirby-Allen; Charles T Quinn; Françoise Bernaudin; Gladstone Airewele; Gerald M Woods; Julie Ann Panepinto; Beng Fuh; Janet K Kwiatkowski; Allison A King; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Hernan Sabio; Corina E Gonzalez; Suzanne L Saccente; Karen A Kalinyak; John J Strouse; Jason M Fixler; Mae O Gordon; J Phillip Miller; Michael J Noetzel; Rebecca N Ichord; James F Casella
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

6.  Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.

Authors:  Vivien A Sheehan; Zhaoyu Luo; Jonathan M Flanagan; Thad A Howard; Bruce W Thompson; Winfred C Wang; Abdullah Kutlar; Russell E Ware
Journal:  Am J Hematol       Date:  2013-05-30       Impact factor: 10.047

7.  Sickle cell disease in western Sudan: genetic epidemiology and predictors of knowledge attitude and practices.

Authors:  Ahmed A Daak; Elfatih Elsamani; Eltigani H Ali; Fatma A Mohamed; Manar E Abdel-Rahman; Abozer Y Elderdery; Octavious Talbot; Peter Kraft; Kebreab Ghebremeskel; Mustafa I Elbashir; Wafaie Fawzi
Journal:  Trop Med Int Health       Date:  2016-03-29       Impact factor: 2.622

Review 8.  G6PD deficiency: the genotype-phenotype association.

Authors:  Philip J Mason; José M Bautista; Florinda Gilsanz
Journal:  Blood Rev       Date:  2007-07-03       Impact factor: 8.250

9.  Alpha-thalassemia is related to prolonged survival in sickle cell anemia.

Authors:  J G Mears; H M Lachman; D Labie; R L Nagel
Journal:  Blood       Date:  1983-08       Impact factor: 22.113

10.  The co-inheritance of alpha-thalassemia and sickle cell anemia is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival.

Authors:  Maryam Bibi Rumaney; Valentina Josiane Ngo Bitoungui; Anna Alvera Vorster; Raj Ramesar; Andre Pascal Kengne; Jeanne Ngogang; Ambroise Wonkam
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

View more
  11 in total

1.  Alpha thalassemia, but not βS-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort.

Authors:  Betânia Lucena Domingues Hatzlhofer; Diego Antonio Pereira-Martins; Igor de Farias Domingos; Gabriela da Silva Arcanjo; Isabel Weinhäuser; Diego Arruda Falcão; Isabela Cristina Cordeiro Farias; Jéssica Vitória Gadelha de Freitas Batista; Luana Priscilla Laranjeira Prado; Jéssica Maria Florencio Oliveira; Thais Helena Chaves Batista; Marcondes José de Vasconcelos Costa Sobreira; Rodrigo Marcionilo de Santana; Amanda Bezerra de Sá Araújo; Manuela Albuquerque de Melo; Bruna Vasconcelos de Ancântara; Juan Luiz Coelho-Silva; Ana Beatriz Lucas de Moura Rafael; Danízia Menezes de Lima Silva; Flávia Peixoto Albuquerque; Magnun Nueldo Nunes Santos; Ana Cláudia Dos Anjos; Fernando Ferreira Costa; Aderson da Silva Araújo; Antonio Roberto Lucena-Araújo; Marcos André Cavalcanti Bezerra
Journal:  Ann Hematol       Date:  2021-02-13       Impact factor: 3.673

2.  Influence of UGT1A1 promoter polymorphism, α-thalassemia and βs haplotype in bilirubin levels and cholelithiasis in a large sickle cell anemia cohort.

Authors:  Jéssica V G F Batista; Gabriela S Arcanjo; Thais H C Batista; Marcondes J Sobreira; Rodrigo M Santana; Igor F Domingos; Betânia L Hatzlhofer; Diego A Falcão; Diego A Pereira-Martins; Jéssica M Oliveira; Amanda S Araujo; Luana P M Laranjeira; Fernanda S Medeiros; Flávia P Albuquerque; Dulcinéia M Albuquerque; Magnun N Santos; Manuela F Hazin; Ana C Dos Anjos; Fernando F Costa; Aderson S Araujo; Antonio R Lucena-Araujo; Marcos A Bezerra
Journal:  Ann Hematol       Date:  2021-02-01       Impact factor: 3.673

Review 3.  Evolutionary history of sickle-cell mutation: implications for global genetic medicine.

Authors:  Kevin Esoh; Ambroise Wonkam
Journal:  Hum Mol Genet       Date:  2021-04-26       Impact factor: 6.150

4.  High fetal hemoglobin level is associated with increased risk of cerebral vasculopathy in children with sickle cell disease in Mayotte.

Authors:  Abdourahim Chamouine; Thoueiba Saandi; Mathias Muszlak; Juliette Larmaraud; Laurent Lambrecht; Jean Poisson; Julien Balicchi; Serge Pissard; Narcisse Elenga
Journal:  BMC Pediatr       Date:  2020-06-20       Impact factor: 2.125

Review 5.  The carrier state for sickle cell disease is not completely harmless.

Authors:  Julia Zhe Xu; Swee Lay Thein
Journal:  Haematologica       Date:  2019-05-16       Impact factor: 9.941

6.  Incidence, kinetics, and risk factors for intra- and extracranial cerebral arteriopathies in a newborn sickle cell disease cohort early assessed by transcranial and cervical color Doppler ultrasound.

Authors:  Françoise Bernaudin; Cécile Arnaud; Annie Kamdem; Isabelle Hau; Fouad Madhi; Camille Jung; Ralph Epaud; Suzanne Verlhac
Journal:  Front Neurol       Date:  2022-09-14       Impact factor: 4.086

7.  Genotypic Diversity among Angolan Children with Sickle Cell Anemia.

Authors:  Mariana Delgadinho; Catarina Ginete; Brígida Santos; Armandina Miranda; Miguel Brito
Journal:  Int J Environ Res Public Health       Date:  2021-05-19       Impact factor: 3.390

Review 8.  Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease.

Authors:  Françoise Bernaudin
Journal:  J Clin Med       Date:  2019-09-22       Impact factor: 4.241

9.  Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach.

Authors:  Charlotte Nazon; Amelia-Naomi Sabo; Guillaume Becker; Jean-Marc Lessinger; Véronique Kemmel; Catherine Paillard
Journal:  J Clin Med       Date:  2019-10-16       Impact factor: 4.241

10.  Comprehensive analysis of mitochondrial and nuclear DNA variations in patients affected by hemoglobinopathies: A pilot study.

Authors:  Ylenia Barbanera; Francesco Arcioni; Hovirag Lancioni; Roberta La Starza; Irene Cardinali; Caterina Matteucci; Valeria Nofrini; Antonella Roetto; Antonio Piga; Paola Grammatico; Maurizio Caniglia; Cristina Mecucci; Paolo Gorello
Journal:  PLoS One       Date:  2020-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.